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Abstract
Background:  Neuroblastic tumors (NBT) derive from neural crest stem cells (NCSC).
Histologically, NBT are composed by neuroblasts and Schwannian cells. In culture, neuroblastic (N-
), substrate-adherent (S-) and intermediate phenotype (I-) cell subtypes arise spontaneously.
Methods:  Here, neuroblastoma (NB) cell line subtypes were characterized according to
embryonic peripheral nervous system development markers (GAP43, Phox2b, Sox10, c-kit, GD2,
NF68, vimentin, S100β, calcyclin and ABCG2), morphological features, gene expression and
differentiation potential. I-type cells were investigated as a bipotential (neuronal and glial)
differentiation stage.
Results:  Positive immunostaining of NCSC (GAP43, c-kit, NF68, vimentin and Phox2b) and
undifferentiated cell (ABCG2) markers was observed in all NB subtypes. N- and I-type cells
displayed cytoplasmic membrane GD2 staining, while nuclear calcyclin was restricted to S-type. N-
and I-type cells showed similar phenotype and immunoreactivity pattern. Differential gene
expression was associated with each cell subtype. N- and I-type cells displayed similar
differentiation capacity towards neuronal and glial lineage fates. S-type cells, upon induction, did not
show a neuronal-like phenotype, despite gene expression changes.
Conclusion: Results suggest that N- and I-type NB cell subtypes represent an immature bilineage
stage, able to progress towards neuronal and glial fates upon induction of differentiation. S-type
cells appear irreversibly committed to a glial lineage fate.
Background
Neuroblastic tumors (NBT) are the most common extrac-
ranial solid tumors in children. NBTs derive from neural
crest stem cells (NCSC) blocked at different stages of the
sympathetic nervous system development [1,2]. Histolog-
ically, NBT are composed of variable proportion of neu-
roblasts (neuronal lineage) and Schwannian-like cells
(glial lineage). Prior studies have reported that both cell
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types share chromosomal abnormalities, suggesting a
common neoplastic precursor cell [3-5] however; discrep-
ant studies failed to detect genetic alterations in the
Schwannian components of NBT [6,7].
The differentiation process of NCSC gives rise to periph-
eral nervous system (PNS), amongst other structures [8,9].
This process can be tracked by analyzing marker proteins
sequentially expressed during embryonic cell develop-
ment [10]. Likewise, the embryonic origin of neuroblastic
tumor cells can be established using NCSC protein mark-
ers such as Phox2b and c-kit [11,12] while embryonic
glial-lineage markers such as SRY box 10 transcription fac-
tor (Sox10) and AP2α are expressed in immature glial
cells in NBT [2].
NBT cell components may be identified using a variety of
protein markers. The glial component may be identified
by the expression of the calcium binding family protein
S100. Specifically, S100A6 (Calcyclin), has been reported
as a neural crest derived glial-cell lineage marker [13], also
expressed in the fetal CNS glia [14]. Calcyclin migrates to
the nuclear membrane upon an increase of intracellular
calcium concentration; its precise function remains
unknown [15]. In NBT, calcyclin expression is mostly
found in Schwann-like cells [16].
The neuronal lineage compartment of NBT is character-
ized by the expression of proteins like neurofilament pro-
teins and the membrane ganglioside GD2 [17-19]. GD2 is
expressed in fetal brain neuroblasts and neuroectodermal
derived tumors. Cell membrane GD2, synthesized by the
GD2 synthase, is implicated in cell adhesion [20].
Biedler [21] described three cell subtypes spontaneously
arising in NB cell line cultures, the N (neuroblastic), S
(substrate adherent) and I (intermediate) subtypes. These
three cell line subtypes were isolated and characterized on
the basis of the different cell culture behavior and protein
expression pattern [21,22]. I-type cell lines, reported to
have a bipotential capacity to differentiate towards both
neuronal and glial lineage when induced with retinoic
acid and bromodeoxyuridine respectively, have recently
been proposed as NBT stem cells [23,24]. Retinoic acid is
a vitamin A derived molecule, which plays an important
role in the early development of the nervous system stim-
ulating neuronal differentiation and inducing the expres-
sion of neuronal proteins [25]. Bromodeoxyuridine is a
thymidine analog which incorporates into the newly syn-
thesized DNA during the S phase of cell cycle. It has been
used as a glial differentiation factor in vitro for NB, induc-
ing cell flattening and increased substrate adhesiveness
[23,26,27].
In this study, we aimed to characterize each NB cell line
subtype according to differential lineage markers from the
embryonic development of PNS and test whether the
intermediate subtype of NB derived cell lines reproduce a
distinct and bipotential (neuronal and glial) stage of dif-
ferentiation. A continuum process of differentiation
between neuronal and glial lineage, which resemble the
normal PNS development, was identified.
Results
Cell lines characterization
Eleven cell lines were investigated. In addition to morpho-
logical and in vitro behavior features, cell lines were char-
acterized based on the differential expression of
previously described markers [11,23] using immunofluo-
rescent staining (Table 1) and qRT-PCR analysis.
Distinct morphological features were observed for S- and
N-type cell lines, as previously described [21]. S-type cell
lines were morphologically characterized by large flat
Table 1: Immunophenotypical analysis of neuroblastoma cell lines
GD2 NF68 Calcyclin Phox2b c-kit Vimentin GAP43 ABCG2
N-type LA1-55N M++ C+ CN C + C++ C+ C+
LAN-1 M++ C+ CN / C + C+ C++ C+ C+
SH-SY5Y M++ C+ C‡ N C+ C++ C+ C+
Be2-M17V M++ C+ C‡ N C+ C++ C+ C+
I-type SK-N-JD M++ C+ CN + CC ++ C+ C+
SK-N-ER M++ C+ C‡ N/C+ C+ C++ CC +
SK-N-Be(2)C M++ C+ CN + C+ C++ C+ C‡
SK-N-LP M++ C+ C‡ N+ C+ C++ CC +
S-type SK-N-AS C N++ N/C+ C+ C++ CC +
SH-EP1 C N++ N/C C C++ CC
LA1-5S - C N++ N/C+ CC ++ CC
M: membrane; C: cytoplasm; N: nuclei; -: no staining; ‡: some nuclei positive; : some cell membrane positive; +: moderate staining; ++: intense 
stainingBMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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cytoplasms, relaxed chromatin and strong adherence to
the flask surface. N- and I-type cell lines showed a very
similar phenotype in culture, characterized by a low cyto-
plasm/nuclei ratio, poor adherence to the flask surface,
growth in dense cell aggregates and neurite processes for-
mation. Only one cell line displayed a clear intermediate
phenotype, the I-type cell line SK-N-ER, characterized by
a larger cytoplasm and greater adherence to the flask sur-
face than the other I-type cell lines, features resembling
those of the S-type cell lines.
Amongst the NBT cell line subtypes the intermediate neu-
rofilaments and vimentin have been proposed as differen-
tially expressed markers for neuronal and glial
phenotypes, respectively [11]. As shown in figure 1, both
proteins are expressed in the cytoplasm of the three cell
subtypes. The neurofilament NF68 showed a higher cyto-
plasmic expression in the N- and I cell subtypes (Figure 1).
On the other hand, vimentin was detected with similar
intensity, in the cytoplasm of all the cell lines analyzed
(Figure 1). In our hands, these markers were not helpful
to distinguish amongst the cell lines subtypes.
N- and I-type were immunophenotypically distinguisha-
ble from S-type cell lines based on the differential staining
of GD2 and calcyclin. Similar intense cytoplasm mem-
brane GD2 immunostaining was observed in both N- and
I-type cells, while intense nuclear membrane calcyclin was
Neuroblastic and glial immunophenotype in NB cell line subtypes Figure 1
Neuroblastic and glial immunophenotype in NB cell line subtypes. Neurofilament NF68 cytoplasm expression inten-
sity was higher in N-, I- than in S-type cell lines. Vimentin is expressed intensely in the cytoplasm of the three cell lines sub-
types. GD2 cell membrane and intense nuclear membrane calcyclin staining allows to distinguish between the neuroblastic and 
the glial phenotype. Blue: DAPI, Green: FITC.BMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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identified exclusively in the S-type. N- and I-type showed
a faint diffuse cytoplasm staining for calcyclin (Figure 1).
Thus, among the markers tested, we found cytoplasm
membrane-GD2 and nuclear-calcyclin immunolabelling
as reliable NBT neuroblastic and glial lineage markers,
respectively.
Of note, all but one of the S-type cell lines studied, the
exception being LA1-5S, turned out not to be pure cul-
tures since few morphologically N-type cells, which were
GD2-membrane positive, were identified. S-like cells were
also detected in the N-type cell lines Be2-M17V and SH-
SY5Y (Table 1).
Overall, the N- and I-type cell lines studied showed a very
similar phenotype in culture, with equivalent adherence,
cytoplasm/nuclei ratio, and similar neurite process forma-
tion. N- and I-type cell lines shared a similar immunore-
activity pattern, namely high membrane GD2 staining,
absence of nuclear calcyclin and high neurofilament NF68
(Figure 1).
Protein markers of undifferentiated neural crest derived
cells, such as GAP43, c-kit and Phox2b, as well as the
undifferentiated cell marker ABCG2, were positive in all
the cell line subtypes tested (Table 1). Intense GAP43
immunostaining was detected in the cytoplasm of N-type
cell lines (Figure 2) and two of the four I-type cell lines. S-
type and the rest of I-type cell lines showed a lower inten-
sity of GAP43 cytoplasmic staining (Table 1). Similar
results were observed for c-kit immunostaining (Table 1).
On the other hand, nuclear localization of Phox2b posi-
Neural crest cell markers pattern in NB cell line subtypes Figure 2
Neural crest cell markers pattern in NB cell line subtypes. All cell line subtypes exhibited positive protein expression 
for GAP43, c-kit, Phox2b and ABCG2 immunostaining. Differences in the intensity and localization of these proteins can be 
identified in some of the cell lines (see text). For Phox2b, small squares show non-merged nuclear cell images. Blue: DAPI, 
Green: FITC (ABCG2, GAP43). Red: Cy3 (Phox2b). c-kit (DAB staining).BMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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tivity was identified in the I-type cell lines, in some cells
being very intense. A lower nuclear intensity was identi-
fied for the N- and S-type (Figure 2). ABCG2 exhibited a
moderate diffuse cytoplasmic immunoreactivity in most
of the cell lines analyzed (Figure 2).
To delve further into the differential expression among
cell line subtypes, GD2-synthase and calcyclin mRNA
expression were analyzed by qRT-PCR. GD2-synthase
expression pattern showed differences among the 3 cell
subtypes, being the N-type cells those with the highest
expression followed by the I-type cells and, at lower level,
the S-type cells (Figure 3A). When calcyclin mRNA expres-
sion was quantified, different expression for S-type com-
pared to N- and I-type was found (Figure 3B). These
results confirm those observed by immunofluorescence.
Additional gene expression analyses were performed in
the cell subtypes by qRT-PCR. Neuronal lineage markers,
NF68 and Tuj1, showed the highest expression in N-type
Gene expression pattern in the NB cell linesubtypes Figure 3
Gene expression pattern in the NB cell linesubtypes. Results are displayed as mean expression levels of cell subtypes 
(N-, I- and S-type), obtained from three independent experiments. Quantification was performed relative to the cell line with 
the lowest amplification level. Error bars illustrate the variability amongst the cell lines of each subtype. A. GD2 synthase mean 
expression quantified in relation to LA1-5S. B. Calcyclin mean expression quantified in relation to LA1-55N. C. NF68 mean 
expression quantified in relation to SK-N-ER. D. Tuj1 mean expression quantified in relation to LA1-5S.BMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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cells. I-type cells showed higher expression than S-type for
the NF68 marker (Figure 3C), and lower for Tuj1 (Figure
3D). Sox10, an immature neural crest marker also
expressed in glial cells, did not show detectable expression
by qRT-PCR in any of the cell lines analyzed, regardless of
the cell type (data not shown).
Altogether, the observed gene expression patterns confirm
the inmunofluorescent results underscoring the imma-
ture, yet distinct, nature of these NBT cell lines. Nonethe-
less, I-type cell lines share features closer to the N-type
subgroup, namely immature neuronal lineage phenotype,
whilst S-type cell lines embody a glial immature stage.
Differentiation Studies
To investigate the behavior of the different cell subtypes
during differentiation induction, LA1-55N (N-type), SK-
N-Be2C, SK-N-LP and SK-N-ER (I-type), and LA1-5S (S-
type) were chosen to represent each cell subtype.
I. Neuronal differentiation induced by all-trans retinoic 
acid (ATRA)
I.a. Morphological and immunophenotypical changes
When differentiation was induced towards neuronal line-
age by treatment with ATRA, both N- and I-type cell lines
changed their morphology. One week after treatment
most cells showed a neuronal-like phenotype, displaying
long and growing neurites. These cells proliferated form-
ing large, dense interconnected cell clumps that were
eventually released as floating spherical cell aggregates,
neurospheres, with capacity to grow in suspension (Figure
4A and 4B). In the N-type, changes appeared early in the
first week of treatment and persisted during all the differ-
entiation induction experiment (60 days). All the I-type
cells showed morphological changes, the most remarka-
ble being in the SK-N-Be2C cell line. During the first week
of treatment neurites grew significantly, and, after two
weeks, floating neurospheres appeared. The I-type SK-N-
LP cell line did not form neurospheres, but poorly adher-
ent cell clusters. In the I-type SK-N-ER cell line, the mor-
phological changes appeared later and around the 5th
week of treatment they formed neurospheres. In all the N-
and I-type cell lines, the morphological changes remained
evident even when ATRA treatment was removed; how-
ever, the capacity to form neurospheres was clearly dimin-
ished. Overall, no significant change in the proliferation
ratio was detected in the cell lines during treatment, how-
ever, an increase in cell mortality was observed after one
week of treatment.
Both N- and I-type cell lines showed no variation of the
membrane-GD2 immunostaining during ATRA treatment
in comparison to non-treated control cell lines. GD2 cell
membrane staining was observed in all the newly formed
neurospheres (Figure 4C). For S-type cells, no GD2 stain-
ing was observed during the entire neuronal induced dif-
ferentiation experiment. No changes of ABCG2 and NF68
neurofilament immunostaining was detected in the cell
lines.
In all the N- and I-type cell lines, some nuclear calcyclin
positive cells were detected during ATRA induced neuro-
nal differentiation. S-like cells were initially detected in
the periphery of the adhered neuronal clusters (Figure
4D). Throughout the induction of neuronal differentia-
tion, these nuclear-calcyclin positive cells increased in
number and acquired S-type morphology, enabling us to
isolate them attached to the flask taking advantage of their
greater capacity of adherence. However, when isolated
from the neuronal cells, these potentially S-type cells
stopped growing and died after 2–3 weeks. New aliquots
of the cell lines tested were thawed and treated separately
to verify whether the presence of nuclear-calcyclin positive
cells was not due to cross contamination. Furthermore,
non-treated control cell lines were studied in parallel and
did not show any of the abovementioned changes
observed during the ATRA treatment. Repeated experi-
ments demonstrated that newly induced S-like cells arise
in response to ATRA treatment.
The S-type cell line LA1-5S showed no apparent changes
when treated with ATRA. It did not show changes in mor-
phology, continued to be adherent to the flask and pre-
served a flat and large cytoplasm. However, calcyclin
nuclear membrane staining decreased during treatment
and was re-established upon ATRA removal.
I.b. Calcyclin, GD2 synthase and SOX10 gene expression changes
To further investigate changes induced during ATRA dif-
ferentiation assays, mRNA levels of relevant genes like cal-
cyclin, GD2 synthase and SOX10 were analyzed by qRT-
PCR at different time points in the three cell subtypes
(LA1-55N, SK-N-Be2C, SK-N-ER and LA1-5S).
ATRA treatment induced an increase of calcyclin transcript
levels in the N-type LA1-55N cell line. The I-type cell line,
SK-N-ER, displayed a peak of expression (more than 2-
fold) at day 3 of treatment (Figure 4E). The S-type cell line,
LA1-5S, showed a slow decrease of the calcyclin expres-
sion level after 3 days of treatment, with a recover of
expression detected at day 7 when ATRA was removed
(Figure 4E). In the I-type SK-N-Be2C cell line, calcyclin
mRNA expression was undetectable by q-PCR until day
60, when an increase of expression was detected that
decreased again to undetectable levels after ATRA deple-
tion (data not shown).
GD2 synthase expression increased during ATRA treat-
ment in N- and I-type cell lines, with a significant increase
in the LA1-55N cells. However, LA1-5S showed a minorBMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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Morphological, immunophenotypical and gene expression changes induced by ATRA Figure 4
Morphological, immunophenotypical and gene expression changes induced by ATRA. Neuronal differentiation in 
the I-type cell line SK-N-Be2C: A. 60 days of ATRA treatment. Arrow: neurosphere in formation. B. not-treated negative con-
trol culture. C. GD2 expression in newly formed floating neurosphere at day 15 of ATRA treatment. D. Calcyclin expression 
at day 60 of ATRA treatment. White arrow: calcyclin positive cell that appear during neuronal differentiation induction treat-
ment. Gene expression changes of calcyclin (E) and GD2 synthase (F) in LA1-55N, LA1-5S and SK-N-ER cell lines. q-RT-PCR 
analysis was performed by triplicate of two separate differentiation experiments (60 days induction and 30 days of treatment 
depletion (90). RA-IND: ATRA induction period.BMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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increase, with a 1.49–0.85 fold variation of expression lev-
els with respect to non-treated controls (Figure 4F).
SOX10 expression was studied in order to clarify the new
appearance of S-like cells during neuronal-lineage
induced differentiation experiments. SOX10 mRNA was
undetectable by q-PCR in all the cell lines tested, both in
the treated as well as in the non-treated controls cell lines
(data not shown).
Taken together, these results show that I-type and N-type
cells display a similar behavior when neuronal differenti-
ation is induced, both showing the capacity to differenti-
ate along the neuronal lineage. On the other hand, for S-
type cells, no neuronal-like phenotype was observed,
despite the gene expression changes detected. The S-like
cells arising during neuronal lineage induced differentia-
tion suggest the bipotential capacity of some of the neu-
roblastic cells in both N- and I-type cultures.
II. Bromodeoxyuridine (BrdU) induced glial differentiation
In order to evaluate the capacity of each of the cell lines to
differentiate towards glial lineage, BrdU was used as pre-
viously described [11,26].
II.a. Morphological and immunophenotypical changes
After one week of BrdU treatment, morphological changes
became apparent. N- and I-type cell lines acquired an S-
like morphology, large flat cytoplasm, and augmented
adherence to the flask surface (Figure 5A). The S-type cell
line did not show any apparent changes. Immunopheno-
typically, the N- and I-type cell lines showed a decrease of
GD2 staining at day 7 of BrdU treatment in comparison to
the non-treated control culture (Figure 5B). Calcyclin
staining in the nuclear membrane appeared in some cells
one week after induction, corresponding with the occur-
rence of the above mentioned changes (Figure 5C). Like-
wise, in all the cell lines subtypes, N, S and I, cytoplasmic
Sox10 staining increased during treatment and at 3 weeks
some nuclear positive cells appeared (Figure 5D). Specifi-
cally, S100 staining showed a slight increase during BrdU
differentiation, increasing the cytoplasmic staining and
showing nuclear staining in some cells after 21 days of
treatment (Figure 5E). These changes were not detected in
the non treated control cells.
After 3–4 weeks of treatment, all N, I, and S cell lines
showed a degenerated morphology, characterized by large
cytoplasms, multinucleated cells and a moderate decrease
of their growth rate. Narath et al. (2007) [28] have
recently described this morphology associated to senes-
cence in neuroblastoma cell lines. In order to test whether
S-like induced cells were senescent, SA-β-galactosidase test
was performed. A significant increase of senescent cells
was observed only at day 21 of BrdU treatment. Specifi-
cally, after 15 days of treatment, less than 1% of cells were
senescent (SA-β-GAL positive cells) in most of the cell
lines studied; the same proportion was observed in non-
treated control cells. However, after 21 days of treatment,
50–80% of cells were positive for SA-β-GAL (Figure 5F) in
LA1-55N, LA1-5S and SK-N-Be2C and, only 15% of senes-
cent cells were detected in the I-type cell line SK-N-ER.
II.b. Calcyclin, GD2 synthase and SOX10 gene expression changes
Gene expression analyses of calcyclin, GD2 synthase and
SOX10 (Figure 6) were performed in all 3 cell lines sub-
types. A 21-day time course was used for these experi-
ments due to the state of cellular degeneration detected
after three weeks of treatment. Days 1, 3, 5, 7, 15 and 21
were analyzed by qRT-PCR.
GD2 synthase expression showed a significant decrease in
LA1-55N and LA1-5S, N- and S-type respectively. In, SK-
N-ER (I-type), GD2 synthase mRNA level decreased after
the 5th day of BrdU treatment, but not as dramatically as
for the other cell subtypes (Figure 6A). On the other hand,
calcyclin gene expression showed a progressive increase in
all the cell lines during treatment. The major increase was
observed in the N-type cells. The I-type cell line, SK-N-ER,
and the S-type, LA1-5S showed a progressive increase of
calcyclin expression (Figure 6B). However, SOX10
showed a great increase of mRNA levels within the first
week of treatment, followed by a fast decrease in all the
cell lines tested (Figure 6C).
Taken together, BrdU differentiation results suggest the
capacity of N- and I-type cell lines to differentiate towards
a glial lineage phenotype.
Discussion
The neural-crest is a vertebrate-specific transient embry-
onic tissue that gives rise to several cell types [29]. It has
been clearly established that early neural-crest cells are
multipotent at the cellular level [30], and perhaps in
reflection of the innate multipotency, neural-crest derived
cells display long lasting plasticity during embryonic
development [31]. This plasticity is also reflected in the
phenomenon of transdifferentiation, whereby cells
change from one unique phenotype into another without
going through a developmentally less mature stage [32].
Neural-crest derived tumors like NBT as well as NBT cell
lines show many of the cell phenotypes characteristic of
the developing neural crest cells: cellular heterogeneity,
plasticity and transdifferentiation capacity [24].
Normal embryogenesis of the PNS involves a bilineal
stage of cell differentiation whereby early glial and neuro-
nal markers can be found coexpressed [10]. In neuroblas-
toma, I-type cells have been described to exhibit an
intermediate morphological and in vitro behavior, sharingBMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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Morphological and immunophenotypical changes induced by BrdU glial differentiation treatment Figure 5
Morphological and immunophenotypical changes induced by BrdU glial differentiation treatment. A. Morpho-
logical changes in SK-N-ER cells (Phase contrast microscopy; 100×). B. GD2 expression levels after 15 days of treatment in I-
type cell line SK-N-Be2C. C Calcyclin, (D) Sox10 and (E) S100 expression after 21 days of BrdU treatment in N-type cell line 
LA1-55N. F. SA-β-GAL positive cells (arrow) after 21 days of BrdU treatment in the I-type SK-N-ER (Phase contrast; 100×). 
Control cell images are reported in the small squares. Scale bar: 50 μm.BMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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Quantitative RT-PCR analysis of gene expression changes induced by BrdU treatment in NB cell line subtypes Figure 6
Quantitative RT-PCR analysis of gene expression changes induced by BrdU treatment in NB cell line subtypes. 
Gene expression changes of GD2 synthase (A), calcyclin (B) and Sox10 (C) in LA1-55N, LA1-5S and SK-N-ER cells. q-RT-PCR 
was performed by triplicate of two separate differentiation experiments (21 days induction).BMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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characteristics of both N- and S-type cells, and express
neuronal as well as glial lineage markers, and to reproduce
a distinct and bipotential (neuronal and glial) stage of dif-
ferentiation [11,24].
Instead of neurofilaments and calcyclin, we found cyto-
plasm membrane-GD2 and nuclear-calcyclin as reliable
NBT neuroblastic and glial lineage markers, respectively.
By immunofluorescence, N- and I-type showed similar
pattern of expression with high GD2 and undetectable
calcyclin. On the other hand, S-type exhibited a high
nuclear-membrane calcylin staining and no ganglioside
GD2 expression. I-type cells represent thus, a distinct NB
cell subpopulation, an intermediate state between the
neuronal and glial lineages, however closer to neuroblas-
tic lineage.
In this study, we aimed to characterize each NBT cell line
subtype according to differential lineage markers from the
embryonic development of PNS. Initially, lineage markers
such as vimentin and GAP43 (glial and neuronal, respec-
tively) were studied. In our hands, these proteins did not
display differential expression between the different cell
subtypes. An undifferentiated state of the cell lines was
studied by using neural crest cells markers such as c-kit
and Phox2b. These proteins displayed positive immunos-
taining in all the cell lines subtypes, suggesting a deriva-
tive from an immature state, comparable to neural crest
cells.
NB cell lines can be induced to differentiate along many
neural crest cell lineages like chromaffin cells, Schwann
cells, melanocytes and neurons [33,34]. Differentiation
inducers towards neuronal lineage like ATRA or glial line-
age like BrdU have been thoroughly described in NBT
[22,11,35]. We showed that, upon ATRA treatment, both
N- and I-type cell lines can be induced to differentiate
towards a neuronal-like lineage, while, no neuronal-like
phenotype was observed in the S-type cell line, despite the
gene expression changes detected.
Furthermore, with BrdU treatment, our results for N- and
I-type cell lines showed a similar shift towards a glial-like
phenotype (S-type shape, reduced GD2 and increase of
glial-lineage markers) for both cell subtypes. Recently,
Narath et al. (2007) [28] described cellular senescence in
MYCN amplified F-type NBT cells after 6 weeks of hydrox-
yurea treatment. F-type cells share some morphological
features with the S-type cells. In our experiments, the
abnormal aspect of BrdU treated cells and proliferation
arrest after few weeks of treatment suggested that long
exposition to BrdU might induce senescence. Our results,
however, demonstrate that BrdU induced bona fide glial
differentiation for the first two weeks of treatment. After
longer exposure (3 weeks) to BrdU, senescence was
induced.
In order to further correlate the embryonic development
of the PNS and the in vitro model, we studied Sox10
induction. Sox10, which is expressed in NCSC and a sub-
set of neural-crest derived lineages, plays a key role in
maintaining pluripotency and inhibiting premature dif-
ferentiation at the stem cell stage. In vivo, glial-lineage dif-
ferentiation is a default program during the NCSC
differentiation pathway towards a neuronal fate [10].
Downregulation of SOX10 is a prerequisite for neuronal
lineage differentiation and its expression is maintained in
the terminally differentiated glial cell [36,10]. Our results
show that SOX10 is undetectable in all cell lines and ATRA
treatment does not activate SOX10 expression. However,
SOX10 expression is induced when glial differentiation is
promoted by BrdU treatment with a fast increase of
SOX10 expression in the S-type cell line and slower but
significant increase in the N- and I-type cell lines.
Our results suggest that N- and I-type NB cells represent
an immature bilineage stage, able to progress towards
neuronal as well as glial fates upon induction of differen-
tiation.
In addition to neurite elongation, neuron specific protein
and gene expression induction, when N- and I-type cell
lines were induced to differentiate with ATRA, two phe-
nomena appeared concomitantly: clumps floating
spheres similar to the previously described neurospheres
[11] and newly formed S-type cells. Neurospheres forma-
tion has been previously reported to occur spontaneously
in N-type cell lines [11]. The spontaneous or induced for-
mation of neurospheres or big floating cell clusters has
been described related to neural stemness [37]. Ongoing
experiments in our laboratory are investigating whether
the differentiating neurospheres contain multipotent
stem-like cells.
Concurrently to neuroblastic cells clustering, S-like cells
appeared in the periphery of these cell clusters. Motohashi
et al., (2007) [38] have recently reported the presence of
glial cells in ATRA treated NCSC cultures. Neuron-glia
interactions control several processes in brain develop-
ment, such as neurogenesis, myelination, synapse forma-
tions and neuronal migration, proliferation and
differentiation [39,40]. During PNS development neuro-
nal and glial differentiation are interdependent and the
fates of these two types of cells are inextricably entangled.
Moreover, in neuroblastoma, it has been hypothesized
that Schwann cells release factors that could induce neu-
ronal differentiation, providing better prognosis [41]. Our
results, first the appearance of S-like cells during induc-
tion of differentiation with ATRA in N- and I-type cells,
and second the incapacity of these cells to survive devoid
of N-/I-type cells, suggest a necessary cross-talk between
immature neuron-glia in neuroblastoma tumor cells
upon induced differentiation.BMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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Overall, our findings highlight how N- and I-type cells
possess a similar differentiation potential, and represent
an uncommitted stage between neuronal and glial fates,
whereas S-type cells seem to be committed towards a glial
lineage fate. These comparable characteristics display,
however, a degree of variability within and amongst the
N- and I-cell line subtypes suggesting a continuum proc-
ess in the differentiation program reproduced by the cell
lines.
Conclusion
In summary, the characterization of each NB cell line sub-
type showed how all three cell lines represent an imma-
ture stage of the neural crest. However, both N- and I-type
phenotypes are consistent with immature multilineage
potential cells, since, upon induction, are able to progress
towards neuronal as well as glial fates. By immunopheno-
type I-type cells did not show an intermediate pattern sug-
gesting a distinct bipotential stage (neuronal and glial),
although differential gene expression analysis revealed
clear differences between the 3 subtypes. S-type cell lines,
on the other hand, appear irreversibly committed towards
glial lineage.
Methods
Tissue culture and cell lines
Phenotype characterization studies were performed on
four N-type human neuroblastoma cell lines (LAN-1,
LA1-55N, Be2-M17V and SH-SY5Y), four I-type cell lines
(SK-N-Be2C, SK-N-JD, SK-N-LP and SK-N-ER) and three
S-type (LA1-5S, SH-EP1 and SK-N-AS). All cell lines except
SK-N-AS (Sigma, US), were kindly provided by Dr. B.
Spengler, Fordham University, New York, NY; and Dr.
NK. V. Cheung, Memorial Sloan-Kettering Cancer Center,
New York, NY.
Cell lines were grown in RPMI high glucose media supple-
mented with 10% FBS, 2 mM L-glutamine and penicillin
(100 U/ml) and streptomycin (100 μg/ml) (Reactiva,
Spain) at 37°C in 5% CO2 atmosphere. Cell lines were
never cultured more than 40 passages after thawing.
Immunofluorescence
Cell lines were plated on round glass cover slips and incu-
bated overnight at 37°C, then washed with PBS, fixed in
4% paraformaldehyde for 20 min, permeated with 0,1%
Triton X-100 for 15 min, when required, and blocked for
30 min with 1% BSA. Primary antibodies, GD2 (BD, US),
calcyclin (Sigma, US), NF68 (Zymed, US) Phox2b (Santa
Cruz, US), GAP43 (Santa Cruz, US), ABCG2 (Alexis Bio-
chemicals, Switzerland) and vimentin (Novocastra, UK)
(Additional Table 1) were incubated for 1–3 h at room
temperature or overnight (O/N) at 4°C and fluoro-
chrome-linked secondary antibody was incubated for 45
min. Nuclear staining was obtained with 4'6-diamino-2-
phenylindole (DAPI) 1:5000 in PBS (Sigma, US). Cells
were mounted in Vectashield Mounting media (Vector
Laboratories, US). Immunofluorescence was examined
with a Leica epifluorescence DM5000B microscope (Leica
Microsystems, US).
Immunocytochemistry
Cell lines were cultured and fixed, permeated and blocked
as explained above. Endogenous peroxidases were inhib-
ited with H2O2  for 20 min. Primary antibodies S100
(Novocastra, UK), Sox10 (R&D systems, US) and c-kit
(Zymed, US)(Additional file 1) were incubated for 15
min-O/N and chromogenically stained with Anti-mouse/
rabbit Poly-HRP IHC detection kit (Chemicon, US).
Differentiation assays
Differentiation experiments were performed as previously
described [11]. Briefly, 5·105–106 cells were harvested in
T.75 culture flasks and 1 μM all-trans-retinoic acid (ATRA)
(Sigma, US) or 10 μM 5-Bromo-2'-deoxyuridine (BrdU)
(Sigma, US) were added to cell culture media to induce
neuronal and glial differentiation, respectively. Treatment
was maintained for 60 days by renewing media contain-
ing the drug three times per week. After 60 days, drug treat-
ment was removed and cell cultures were maintained for
30 more days in media without drug. When treated with
ATRA, cells were trypsinized at least once per week. For the
two initial weeks, we also harvested different amounts of
cells for immunofluorescence studies (2.5·105–106 cells)
and mRNA extraction (2.5·105–3·106 cells). For the rest
of time points we obtained the cells directly from the T.75
flasks.
Cell samples were harvested at days 1, 3, 5, 7, 15, 30, 60
and 30 days after treatment removal to analyze target
markers. Control cell cultures, maintained without drug
treatment, were harvested in parallel with drug-cultured
cells. The experiments were performed in duplicate. See
Additional file 2 for a flow-sheet diagram of differentia-
tion experiments.
Senescence analysis
Senescence of cells during differentiation experiments was
analyzed by the senescence associated-β-galactosidase test
kit (Sigma, US) based on Dimri protocol [42]. Briefly,
cells were fixed in 2% glutaraldehyde/20% formaldehyde
and then stained O/N with X-gal staining solution. Blue
cells were considered positive. Non-treated cells cultured
in parallel were used as control.
Quantitative RT-PCR (qRT-PCR)
Quantification of transcript levels was performed for cal-
cyclin, GD2 synthase, and SOX10. For GD2 synthase and
calcyclin expression analyses all non-treated and differen-
tiation induced cell lines LA1-55N, SK-N-ER and LA1-5S
were used and, for SOX10 only the differentiation
induced cell lines mentioned above were analyzed. RNABMC Developmental Biology 2009, 9:12 http://www.biomedcentral.com/1471-213X/9/12
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was isolated using Tri Reagent (Sigma, US), following
manufacturers' protocols. cDNA was synthesized from 1
μg total RNA using random hexamers (Applied Biosys-
tems, US) and M-MLV reverse transcriptase (Promega,
US). q-PCR reactions (40 ng cDNA) and quantification,
using the ΔΔCT relative quantification method, were per-
formed on an ABI Prism 7000 Sequence Detection System
using Assay-on-Demand Gene Expression products
(Applied Biosystems, US). GD2 synthase primers and
probes were described elsewhere [43]. Transcript levels
were normalized to TATA box binding protein (TBP)
expression values [44] and quantified relative to the cell
line with the lowest amplification level or to each time
course day non-treated control, in differentiation experi-
ments. TBP coefficients of variation showed a low degree
of variation amongst the cell lines and during the differen-
tiation treatment (CV < 0.05). All experiments included
no template controls and were performed in duplicate
and repeated twice independently.
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